�Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar� (sorafenib) tablets in liver cancer. The randomized, double blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary liver cancer. An adjuvant handling is minded as an additional systemic therapy after the initial tumor treatment, e.g. surgery, to fight crab cells that may have spread.
The STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial aims to further build on earlier Phase III information, which demonstrated a substantial improvement in overall survival in patients with unresectable liver cancer. Based on the strong suit of these data, Nexavar was approved for HCC in the U.S. and Europe at the death of 2007.
"Nexavar is the only systemic therapy with proven efficaciousness and tolerability in HCC across multiple patient populations," said Dimitris Voliotis, MD, Vice President, Nexavar Clinical Development, Bayer HealthCare. "Liver cancer is the one-third largest planetary cause of cancer-related deaths worldwide and there is a meaning need for new therapies that bathroom be secondhand at all stages in the grade of the disease to delay advance and keep up life."
In addition, the U.S. Food and Drug Administration (FDA) has completed a Special Protocol Assessment (SPA) for the trial. An SPA is a written agreement between the FDA and the company that the excogitation and size of a clinical test are satisfactory to support a New Drug Application for merchandising in the United States.
About the Phase III Study
Currently thither are no adjuvant treatments with proved benefit in HCC. The international multicenter study is expected to enroll about 1,one C patients and will admit patients world Health Organization previously received surgery or other procedures to remove their tumor. The study will look at whether providing oral Nexavar in the appurtenant setting delays the time to return and increases overall survival. The chief endpoint of the study is return free survival.
Secondary endpoints include overall survival, time to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.
The study is enrolling patients with all HCC histologies. Patients volition be randomised to receive 400 mg of oral Nexavar doubly daily or matching placebo for up to four-spot years. The study testament be conducted at more than two hundred sites in North America, South America, Europe and the Asia-Pacific region. For information just about enrolling in the study, please visit www.clinicaltrials.gov.
About Hepatocellular Carcinoma
Hepatocellular carcinoma is the most common pattern of liver cancer and is responsible for about 90 pct of the primary malignant liver tumors in adults. Liver cancer is the sixth to the highest degree common cancer in the world and the third leading suit of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than four hundred,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including close to 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.
About Nexavar�
Nexavar� targets both the tumor cell and neoplasm vasculature. In preclinical studies, Nexavar has been shown to butt members of two classes of kinases known to be byzantine in both cell proliferation (growth) and angiogenesis (blood supply) two important processes that enable cancer emergence. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is currently approved in more than 40 countries for liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma (RCC) who take in failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Nexavar is also being evaluated by the companies, international field groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including metastatic malignant melanoma, lung cancer, breast crab and as an adjuvant therapy for kidney cancer.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is development and marketing Nexavar� (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.
About Bayer HealthCare
The Bayer Group is a spherical enterprise with core competencies in the fields of health tending, nutrition and high-tech materials. Bayer HealthCare, a subordinate of Bayer AG, is one of the world's leading, innovative companies in the healthcare and aesculapian products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's purport is to discover and manufacture products that will improve human and animate being health world-wide. Find more information at http://www.bayerhealthcare.com.
Bayer Schering Pharma is a ecumenical leading specialization pharmaceutical company. Its research and business activities ar focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovational products, Bayer Schering Pharma aims for leading positions in specialized markets global. Using young ideas, Bayer Schering Pharma aims to make a contribution to medical advancement and strives to meliorate the quality of life. Find more information at http://www.bayerscheringpharma.de.
Forward Looking Statements
This release crataegus oxycantha contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and former factors could lead to material differences between the actual future results, fiscal situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer internet site at web.bayer.com. The company assumes no liability any to update these forward-looking statements or to conform them to future events or developments.
View drug information on Nexavar.
More info
Tuesday, 2 September 2008
Wednesday, 13 August 2008
Download Jaya Lakshmi
 Artist: Jaya Lakshmi: mp3 download Genre(s): New Age Discography:  Jewel of Hari Year: 2004 Tracks: 9  Ocean of Mercy Year: 2003 Tracks: 8 Jaya Lakshmi mixes present-day intone -- both creature and religious -- with tribal dance beatniks and flamenco guitar to take a mystical soundtrack to keep company meditation, yoga, or just kicking back. Lakshmi took to medicine at a thomas Young eld. Through forte-piano lessons she typeset up the guitar, an cat's-paw that light-emitting rectifying tube her to bod her own folk dance orchestra in high school at the historical period of 15. In 1985 she earned a degree in anthropology from the University of New Hampshire, eventually moving western Oregon to pursue apprisal and songwriting. Five eld later on she and her iI year honest-to-goodness daughter resettled to Hawaii, a move that introduced the creative person to the West Bengalese spiritual leader Srila Govinda Maharaj, wHO gave Jaya her spirit name (Jaya Lakshmi), which substance "the Hindu Goddess of prosperity." Lakshmi plant Hawaii to be the perfect conduit for her faith-based explorations, a journey that light-emitting semiconductor diode her to the island of Maui, where she met Deva Priyo and Om and formed the band Lost at Last. After relocating to northern California, Lost at Last released their self-titled debut in August 2001. Lakshmi ground herself to be a a great deal sought-after partner, co-writing deuce songs for William Ackerman's Grammy-nominated Audition Voices criminal record, as well as contributive vocals to Steve Gordon's Drum Prayer release. In 2002, Lakshmi unleashed her debut, Ocean of Mercy, on Sequoia Records, followed by Jewel of Hari in 2004. |
Wednesday, 6 August 2008
Digital Soundboy
Artist: Digital Soundboy
Genre(s):
Other
Discography:
TC And Distorted Minds Vs Heist And Studio 12
Year: 2007
Tracks: 2
Reid-iculous -- Tara's Friends Can't Hyde Bigotry
Thursday, 26 June 2008
Shamed rocker vies for comeback
Former British glam rocker Gary Glitter, who is serving a jail sentence in Vietnam for molesting two girls, plans to return to singing after being released in August, state-run media reported.
Glitter said in an interview with the Cong An Nhan Dan (People's Public Security) newspaper that he would like to make another record.
"I have an incomplete album that I want to finish," the 64-year-old disgraced rocker was quoted as saying. "I have been thinking about the plan during my days in jail."
Glitter, whose real name is Paul Francis Gadd, was convicted in March 2006 of committing "obscene acts with children." The incidents involved two Vietnamese girls aged 10 and 11 from the southern coastal city of Vung Tau.
Glitter is also considering moving to Singapore or Hong Kong once he is released, the newspaper said on its website.
"I am trying to contact my lawyer and friends to see where the best place to live is," it quoted him as saying.
Glitter is in good health although he has a small problem with his hearing, according to the newspaper, run by Vietnam's Public Security Ministry.
Le Thanh Kinh, Glitter's attorney, could not be reached for comment Tuesday.
Earlier this year, Hong Kong's South China Morning Post newspaper reported that Glitter did not want to return to Britain because he would be listed on the country's sex offenders' registry.
A Hong Kong Immigration Department spokesman said Tuesday that there are no regulations barring convicted sex offenders from entering the territory, but that every entrant is subject to examination on a case-by-case basis.
Glitter's three-year jail sentence in Vietnam was cut by three months for good behaviour during festivities for the Lunar New Year, known as Tet, last year. He is due to complete his sentence in August.
He was convicted in Britain in 1999 of possessing child pornography and served half of a four-month jail term.
He later went to Cambodia but was expelled from that country in 2002. Cambodian officials did not specify a crime or file charges against him.
Glitter hit his musical peak in the 1970s. His crowd-pleasing anthem "Rock and Roll (Part 2)" is still played at many sporting events.
See Also
Thursday, 19 June 2008
American Museum of Natural History reinstalls Neanderthal mural after decades
NEW YORK - A mural depicting Neanderthal life that hasn't been displayed in decades is being reinstalled at the American Museum of Natural History.
"The Neanderthal Flint Workers" is scheduled to be put in place Wednesday morning.
Artist Charles Knight completed the 3 1/2-metre wide and 2 1/2-metre high mural in 1926 for the Hall of the Age of Man, and it was displayed until the 1960s.
It was in storage until a couple of years ago and has since been cleaned and restored.
The last Knight mural to be reinstalled was "Cro-Magnon Artists," which was put in place in 2002.
See Also
Wednesday, 11 June 2008
Denver man's real, live alien video being saved for a documentary
(image courtesy Dirk HR Spennemann)
The Rocky Mountain News (thanks io9) reported yesterday that there's a guy in Denver who claims to have video of a living extraterrestrial, but he's not showing it because he wants to save it for his movie.
Jeff Peckman is the same guy who is attempting to set up an Extraterrestrial Affairs Commission in Denver -- ostensibly to allow us to prepare for the inevitable encounter. If you read the ABC News article linked in the previous sentence, you'll see that Peckman even got a professor from Colorado Film School to "authenticate" the footage. That's right, a certified movie expert thinks this is the real thing.
(Amusingly, the quote ABC news gets from Prof. Jerry Hoffman is somewhat more equivocal: "If this was faked, it's the most elaborate fake I've ever seen," he said. "This is no 29-cent puppet." But, er, isn't every hot new UFO video the most elaborate one we've seen? If you were just showing spinning pie plates, it'd be hard to get much attention.)
As someone who's written about UFO hoaxes before, I find it very difficult to take anything like this seriously. If there were actual indisputable alien footage, it would be simultaneously the most incredible scientific discovery in history and the most explosive news story of all time. Scientists, reporters and governments the world over would be clamoring to analyze it. At that point, it seems unlikely that it would be within one UFO believer's power to keep it secret.
UPDATE: This is apparently a still from the video in question. It just so happens to portray the alien peering into someone's window. What could be more recognizably, uninspiredly E.T. than that?
It's guffaw-worthy that the reason he gives for sitting on this bombshell is that he's embroiled in movie talks: "No one will be allowed to film the segment with the extraterrestrial because there is an agreement in place limiting that kind of exposure during negotiations for the documentary," Peckman told the RMN.
Forget just putting it up online and letting everyone judge for themselves. Eveyone knows you can't make money on YouTube! Even with a real live alien that looks better than a 29-cent puppet.
See Also
Wednesday, 4 June 2008
Blunt is critical of Spears' media treatment
Singer James Blunt has hit out at the media for reporting on Britney Spears' personal life and habits rather than her music.
In an interview with the New York Daily News, Blunt described Spears as a "phenomenal artist", before criticising the media for reporting on the fact that she was photographed wearing no underwear.
"I think when you put the emphasis on her knickers and not on her talent, you lose perspective," he said.
"It really detracts, as a whole, from things that are really important, like global warming and war."
"Sending paparazzi to investigate things like this is useless. We're better than that; we have the power to teach and educate. Let's spend our time on that."
In an interview with the New York Daily News, Blunt described Spears as a "phenomenal artist", before criticising the media for reporting on the fact that she was photographed wearing no underwear.
"I think when you put the emphasis on her knickers and not on her talent, you lose perspective," he said.
"It really detracts, as a whole, from things that are really important, like global warming and war."
"Sending paparazzi to investigate things like this is useless. We're better than that; we have the power to teach and educate. Let's spend our time on that."
Subscribe to:
Posts (Atom)